Evaluation of Extended Wear Hearing Aid for Mild Hearing Loss
Launched by SONOVA AG · Dec 18, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how well extended wear hearing aids help adults with mild sensorineural hearing loss, which is a type of hearing loss caused by problems in the inner ear or nerve pathways. The goal is to see if these hearing aids make it easier for people to listen and understand sounds compared to not using any hearing aid at all.
To participate, you need to be at least 18 years old and currently using Lyric hearing aids, which are designed for extended wear. You should also have mild hearing loss as defined by specific hearing tests. It’s important that you can read, write, and speak English well and are willing to follow the study's guidelines. If you’re interested in joining, you’ll be asked to take part in assessments to see how the hearing aids are working for you. The study is not yet recruiting, so there’s still time to learn more about it before it starts.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Meets requirements outlined on Lyric Candidacy Form
- • Current Lyric hearing instrument user
- • 18 years of age or older at time of enrollment in the study
- • Mild sensorineural hearing loss as defined by WHO, 4 frequency PTA of 20-34 dB HL, in the better hearing ear
- • Good understanding (read/write/speak) of the English language
- • Willingness to comply with all study requirements
- Exclusion Criteria:
- • Does not meet requirements outlined on Lyric Candidacy Form (see Chapter 9 of the TMF/ISF for SRF-469)
- • Difficulty understanding/reading instructions when corrected for vision loss
- • Impairments that would restrict participation in any of the evaluations
- • Ear health conditions present at baseline that prevent immediate device replacement
- • Conditions that would indicate the need for medical referral prior to hearing aid fitting, according to clinic's standard protocol
About Sonova Ag
Sonova AG is a leading global provider of innovative solutions in the field of hearing care and audiology. Headquartered in Switzerland, the company specializes in the development, manufacturing, and distribution of advanced hearing instruments, cochlear implants, and wireless communication systems. With a strong commitment to research and development, Sonova AG focuses on enhancing the quality of life for individuals with hearing loss through cutting-edge technology and personalized care. The organization actively engages in clinical trials to further advance its product offerings and ensure the efficacy and safety of its solutions, reinforcing its position as a trusted leader in the hearing healthcare industry.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shenandoah, Texas, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported